Background: Vascular changes, both endothelial and functional, are crucial events in inflammatory responses. Objectives: To investigate the dynamics of endothelial cell (EC) and functional changes during acute inflammation in an in vivo model of the skin using leukotriene B4. Methods: EC proliferation, vascular network size, vessel diameter (VD), and hypoxia-inducible factor (HIF)-1α were studied by immunohistochemical CD31/Ki67 double staining and single staining of HIF-1α. Cutaneous perfusion (CP) was assessed using the Twente Optical Perfusion Camera. Results: The initial phase illustrated an increase in VD, Ki67+ EC, and HIF-1α expression and late-phase vascular expansion. The HIF-1α and Ki67+ EC expression was limited. CP and VD were augmented after 24 h. Conclusion: The early phase of inflammation is characterized by EC proliferation and HIF-1α expression. Vascular expansion continues over time. CP and VD are seen in both phases of inflammation. Angiogenesis, vascular network formation, and perfusion are time-dependent processes which are mutually related during inflammation.

Keywords:
Angiogenesis, Endothelium, Perfusion, Leukotriene B4
1.
Huggenberger R, Detmar M: The cutaneous vascular system in chronic skin inflammation. J Investig Dermatol Symp Proc 2011;15:24-32.
2.
Zgraggen S, Ochsenbein AM, Detmar M: An important role of blood and lymphatic vessels in inflammation and allergy. J Allergy 2013;2013:672381.
3.
Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, et al: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-1146.
4.
Heidenreich R, Rocken M, Ghoreschi K: Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009;90:232-248.
5.
Marrelli A, Cipriani P, Liakouli V, Carubbi F, Perricone C, Perricone R, et al: Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev 2011;10:595-598.
6.
Creamer D, Sullivan D, Bicknell R, Barker J: Angiogenesis in psoriasis. Angiogenesis 2002;5:231-236.
7.
Braverman IM, Sibley J: Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Investig Dermatol 1982;78:12-17.
8.
Sisto M, Lisi S, Ingravallo G, Lofrumento DD, D'Amore M, Ribatti D: Neovascularization is prominent in the chronic inflammatory lesions of Sjögren's syndrome. Int J Exp Pathol 2014;95:131-137.
9.
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-580.
10.
Bauer SM, Bauer RJ, Velazquez OC: Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovascular Surg 2005;39:293-306.
11.
Yoo SY, Kwon SM: Angiogenesis and its therapeutic opportunities. Mediators Inflamm 2013;2013:127170.
12.
Hashimoto T, Shibasaki F: Hypoxia-inducible factor as an angiogenic master switch. Front Pediatr 2015;3:33.
13.
Collet G, El Hafny-Rahbi B, Nadim M, Tejchman A, Klimkiewicz K, Kieda C: Hypoxia-shaped vascular niche for cancer stem cells. Contemp Oncol (Pozn) 2015;19:A39-A43.
14.
Rezvani HR, Ali N, Nissen LJ, Harfouche G, de Verneuil H, Taieb A, et al: HIF-1α in epidermis: oxygen sensing, cutaneous angiogenesis, cancer, and non-cancer disorders. J Investig Dermatol 2011;131:1793-1805.
15.
Rosenberger C, Solovan C, Rosenberger AD, Jinping L, Treudler R, Frei U, et al: Upregulation of hypoxia-inducible factors in normal and psoriatic skin. J Investig Dermatol 2007;127:2445-2452.
16.
Ioannou M, Sourli F, Mylonis I, Barbanis S, Papamichali R, Kouvaras E, et al: Increased HIF-1α immunostaining in psoriasis compared to psoriasiform dermatitides. J Cutan Pathol 2009;36:1255-1261.
17.
Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC: Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 2011;63:1-9.
18.
Mimouna S, Goncalves D, Barnich N, Darfeuille-Michaud A, Hofman P, Vouret-Craviari V: Crohn disease-associated Escherichia coli promote gastrointestinal inflammatory disorders by activation of HIF-dependent responses. Gut Microbes 2011;2:335-346.
19.
Ruzicka T, Simmet T, Peskar BA, Ring J: Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. J Investig Dermatol 1986;86:105-108.
20.
Reilly DM, Parslew R, Sharpe GR, Powell S, Green MR: Inflammatory mediators in normal, sensitive and diseased skin types. Acta Derm Venereol 2000;80:171-174.
21.
Yousefi B, Jadidi-Niaragh F, Azizi G, Hajighasemi F, Mirshafiey A: The role of leukotrienes in immunopathogenesis of rheumatoid arthritis. Mod Rheumatol 2014;24:225-235.
22.
Ziboh VA, Casebolt TL, Marcelo CL, Voorhees JJ: Biosynthesis of lipoxygenase products by enzyme preparations from normal and psoriatic skin. J Investig Dermatol 1984;83:426-430.
23.
Kumar NS, Schaefer PA, Lark G, Frieri M: Late phase response during nasal challenge: effect of astemizole on leukotriene B4 levels. Allergy Asthma Proc 1996;17:93-99.
24.
Ohnishi H, Miyahara N, Gelfand EW: The role of leukotriene B4 in allergic diseases. Allergol Int 2008;57:291-298.
25.
Lewis RA, Austen KF, Soberman RJ: Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-655.
26.
Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, et al: Requirement of a 5- lipoxygenase-activating protein for leukotriene synthesis. Nature 1990;343:282-284.
27.
Yokomizo T, Izumi T, Shimizu T: Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys 2001;385:231-241.
28.
Hendriks AG, Keijsers RR, Seyger MM, van de Kerkhof PC, van Erp PE: Cutaneous application of leukotriene B4 as an in vivo model of psoriasis-like skin inflammation: an immunohistological study. Skin Pharmacol Physiol 2014;27:120-126.
29.
Palestro CJ: Radionuclide imaging of osteomyelitis. Semin Nucl Med 2015;45:32-46.
30.
Bleeker-Rovers CP, Boerman OC, Rennen HJ, Corstens FH, Oyen WJ: Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr Pharm Des 2004;10:2935-2950.
31.
Draijer M, Hondebrink E, van Leeuwen T, Steenbergen W: Twente Optical Perfusion Camera: system overview and performance for video rate laser Doppler perfusion imaging. Opt Express 2009;17:3211-3225.
32.
van der Post RS, van der Laak JA, Sturm B, Clarijs R, Schaafsma HE, van Krieken JH, et al: The evaluation of colon biopsies using virtual microscopy is reliable. Histopathology 2013;63:114-121.
33.
Fraga A, Ribeiro R, Principe P, Lopes C, Medeiros R: Hypoxia and prostate cancer aggressiveness: a tale with many endings. Clin Genitourin Cancer 2015;13:295-301.
34.
Wobser M, Siedel C, Kneitz H, Brocker EB, Goebeler M, Houben R, et al: Microvessel density and expression of vascular endothelial growth factor and its receptors in different subtypes of primary cutaneous B-cell lymphoma. Acta Derm Venereol 2013;93:656-662.
35.
Zheng J, Song F, Lu SL, Wang XQ: Dynamic hypoxia in scar tissue during human hypertrophic scar progression. Dermatol Surg 2014;40:511-518.
36.
Hendriks AG, van de Kerkhof PC, de Jonge CS, Lucas M, Steenbergen W, Seyger MM: Clearing of psoriasis documented by laser Doppler perfusion imaging contrasts remaining elevation of dermal expression levels of CD31. Skin Res Technol 2015;21:340-345.
37.
Mukhtar H, Bik DB, Ruzicka T, Merk HF, Bickers DR: Cytochrome P-450-dependent omega-oxidation of leukotriene B4 in rodent and human epidermis. J Investig Dermatol 1989;93:231-235.
S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.